On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...

For the first time ever, the FDA has approved a treatment specifically for people with classic congenital adrenal hyperplasia (CAH), a genetic condition that affects the adrenal glands.

Classic congenital adrenal hyperplasia, more commonly called classic CAH, is when there is an enzyme missing in the adrenal gland, which causes the body to have the inability to make enough cortisol.

Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the ... reduce the amount of glucocorticoid treatment needed, which, according to ...

Sexual precocity and a testicular mass can result from a Leydig cell tumor or from simple virilizing CAH with adrenal rests in ... Glucocorticoid treatment failed to suppress 170HP and T, and ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

Neurocrine Biosciences announced that the FDA has approved crinecerfont as an adjunct to glucocorticoid replacement to control androgens for patients with congenital adrenal hyperplasia.